

Global Phase 1 Clinical Development of SNB-101, a Novel Therapeutic for Small Cell Lung Cancer

SN BioScience Inc.



ONCOLOGY	Phase 1
Product Type	Small molecules
Indication	Small Cell Lung Cancer
Target	NA
MoA(Mechanism of Action)	Topoisomerase I inhibitor (Lung targeting nanoparticle)
Competitiveness	<ul style="list-style-type: none"> • Outperforms competitors (1st or 2nd line therapeutics) in preclinical. • Outstanding results from phase 1a study in South Korea. • Confirmed efficacy in combination with anti-PD-L1 drug in preclinical. • Superior safety compared with competitors in phase 1a study • Fast track and orphan drug designated from FDA
Development Stage	Phase 1
Route of Administration	Intravenous infusion

Any unauthorized distribution or reproduction of this material is strictly prohibited.